Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
General Neurologist and Subspecialist Care for Multiple Sclerosis, Patients' Perceptions
Neurol 53:1190-1197, Vickrey,B.G.,et al, 1999
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996